Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement

Sensei Biotherapeutics, Inc.

Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.
Cash and marketable securities $21.2M at Dec 31, 2025, down from $41.3M at Dec 31, 2024.
Completed acquisition of Faeth Therapeutics; adds oral PIKTOR candidate targeting PI3K/AKT/mTOR.
Concurrent $200M private placement supports Phase 2 endometrial and Phase 1b breast cancer trials.
Topline data from Phase 2 endometrial and start of Phase 1b breast cancer expected by year-end 2026.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-130419
form_type: 8-K
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2026-03-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.419950+00:00
generated_at: 2026-05-15T08:26:08.010443+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-130419
json_url: https://secwatch.observer/filing/0001193125-26-130419.json
markdown_url: https://secwatch.observer/filing/0001193125-26-130419.md
text_url: https://secwatch.observer/filing/0001193125-26-130419.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/0001193125-26-130419-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/d118677d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-130419

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.